Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

July 27, 2017July 27, 2017

MPM Avastin and Pemetrexed/Cisplatin Combo Therapy May Not Make Economic Sense for Chinese Patients, Study Says

News

Adding Avastin (bevacizumab) to a chemotherapy regimen with pemetrexed/cisplatin may not be a cost-effective choice to treat malignant pleural mesothelioma (MPM), according to a new Chinese study. The study, “Cost-effectiveness ... Read more

July 26, 2017July 26, 2017

Anetumab Ravtansine Is Unable to Outperform Vinorelbine as a Mesothelioma Treatment, Trial Shows

News

Bayer’s anetumab ravtansine failed to improve the time it took for mesothelioma patients’ disease to progress, compared with another chemotherapy, according to a Phase 2 clinical trial. The results applied ... Read more

July 17, 2017

Researchers Call for Phase 3 Trials of CDK4/6 Inhibitors as Treatments for Malignant Mesothelioma

News

CDK4/6 protein inhibitors, which have proven effective against some cancers, might be a way to treat malignant mesothelioma, according to a review in the journal Genes & Cancer. They called ... Read more

May 18, 2017

Duration of Asbestos Exposure Influences Risk of Pleural Mesothelioma

News

Workers who are exposed to asbestos early in their career are at higher risk of developing pleural mesothelioma (PM) than those who were exposed later in their career, or at ... Read more

April 18, 2017April 18, 2017

Midkine Protein Levels May Predict Prognosis in Mesothelioma Patients, Says Turkish Study

News

Blood levels of the protein mesothelin have moderate sensitivity and high specificity in distinguishing malignant pleural mesothelioma (MPM) from other pleural diseases, but levels of a protein called midkine may ... Read more

April 6, 2017April 6, 2017

Novocure’s STELLAR Trial Enrolls Last Mesothelioma Patient to Test Tumor Treating Fields, Chemotherapy Combo

News

Novocure has enrolled its last patient in the STELLAR trial (NCT02397928) to assess the safety and effectiveness of Tumor Treating Fields (TTFields) in combination with standard chemotherapy in newly diagnosed, ... Read more

April 5, 2017April 5, 2017

MPM Tumors Are Genetically Heterogeneous, Triggering Unique Responses from Immune System

News

Each malignant pleural mesothelioma (MPM) tumor site harbors different genetic mutations, and each one triggers a specific immune system’s response, according to a recent study by the University of Chicago’s ... Read more

March 23, 2017

MS Therapy Fingolimod Reduces Mesothelioma Tumor Size in Mice, Study Shows

News

The multiple sclerosis therapy Fingolimod (FTY720) reduced tumor size in a mouse model of malignant mesothelioma (MM), a study demonstrated. The research, “FTY720 Inhibits Mesothelioma Growth In Vitro And In A ... Read more

March 14, 2017March 15, 2017

Full Transcript of Interview with Sellas on Galinpepimut-S Vaccine Being Tested for MPM

News

Mesothelioma Research News interviewed Angelos Stergiou, MD, ScD, CEO and vice chairman of the board, and Nicholas Sarlis, MD, PhD, senior vice president and chief medical officer of Sellas Life ... Read more

March 14, 2017March 15, 2017

Sellas Shares Plans for Phase 3 Study of Galinpepimut-S Vaccine in MPM Patients

News

Bermuda-based Sellas Life Sciences Group will conduct a Phase 3 clinical trial to investigate the efficacy and safety of the galinpepimut-S vaccine as a potential treatment for patients with malignant pleural ... Read more